Cargando…

Cost-Effectiveness Analysis of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease in Canada

INTRODUCTION: To evaluate the cost-effectiveness of evolocumab when added to standard of care lipid-lowering treatment (LLT) for patients with atherosclerotic cardiovascular disease (ASCVD) who cannot adequately control their low-density lipoprotein cholesterol (LDL-C) despite optimized LLT in Canad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grégoire, Jean, Champsi, Salimah, Jobin, Manon, Martinez, Laura, Urbich, Michael, Rogoza, Raina M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239938/ https://www.ncbi.nlm.nih.gov/pubmed/35604523 http://dx.doi.org/10.1007/s12325-022-02130-4

Ejemplares similares

Prevalence of atherosclerotic cardiovascular disease and subsequent major adverse cardiovascular events in Alberta, Canada: A real‐world evidence study
por: Chen, Guanmin, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia
por: Alghamdi, Ahmed, et al.
Publicado: (2021)

Increasing Prevalence and Incidence of Atherosclerotic Cardiovascular Disease in Adult Patients in Ontario, Canada From 2002 to 2018
por: Mackinnon, Erin S., et al.
Publicado: (2021)

Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years*
por: Borissov, Borislav, et al.
Publicado: (2017)

Effects of Evolocumab on Cardiovascular Events
por: Mikhail, Nasser
Publicado: (2017)

Cost‐Effectiveness of LDL‐C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States
por: Gandra, Shravanthi R., et al.
Publicado: (2016)

Evolocumab to reduce cardiovascular events: results of the (FOURIER) multinational trial
por: Shah, Syed Raza, et al.
Publicado: (2017)

Retargeting the management of hypercholesterolemia – focus on evolocumab
por: Colletti, Alessandro, et al.
Publicado: (2016)

Efficacy of Evolocumab in Monogenic vs Polygenic Hypercholesterolemia
por: Lee, Timothy, et al.
Publicado: (2019)

Cost-Effectiveness of Icosapent Ethyl (IPE) for the Reduction of the Risk of Ischemic Cardiovascular Events in Canada
por: Lachaine, Jean, et al.
Publicado: (2023)

Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada
por: Goeree, Ron, et al.
Publicado: (2022)

Profile of evolocumab and its potential in the treatment of hyperlipidemia
por: Cicero, Arrigo FG, et al.
Publicado: (2015)

Maculopapular Exanthema After the Second Dose of Evolocumab
por: Ghernautan, Victoria, et al.
Publicado: (2021)

Analisi di costo-utilità di evolocumab in pazienti con ASCVD in Italia
por: Marcellusi, Andrea, et al.
Publicado: (2021)

Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data
por: Erviti, Juan, et al.
Publicado: (2022)

Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in China
por: Wan, Yuansheng, et al.
Publicado: (2023)

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
por: Blom, Dirk J, et al.
Publicado: (2016)

Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety
por: Lee, Edward, et al.
Publicado: (2019)

Atrial Fibrillation as a Possible Adverse Reaction to Evolocumab
por: Abdelmaseih, Ramy, et al.
Publicado: (2021)

Evolocumab loaded Bio-Liposomes for efficient atherosclerosis therapy
por: Li, Zhenxian, et al.
Publicado: (2023)

Risk stratification of atherosclerotic cardiovascular disease in Chinese adults
por: Yang, Xue-Li, et al.
Publicado: (2016)

Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
por: Rosenson, Robert S., et al.
Publicado: (2016)

Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
por: Kasichayanula, Sreeneeranj, et al.
Publicado: (2018)

Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia
por: Kosmas, Constantine E, et al.
Publicado: (2018)

A Sudden Onset of Severe Thrombocytopenia While Using Evolocumab
por: Inoue, Ikuo, et al.
Publicado: (2020)

Is Deprescription of Ezetimibe Safe in Familial Hypercholesterolemia Patients Taking Evolocumab?
por: Hang, Shyann, et al.
Publicado: (2021)

Evolocumab Effects on Lipoproteins, Measured by High-Performance Liquid Chromatography
por: Masuda, Daisaku, et al.
Publicado: (2020)

EVOLOCUMAB TREATMENT FAILURE FOLLOWING COVID-19 MRNA VACCINATION
por: Park, Byung Joon, et al.
Publicado: (2022)

A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab
por: McDonagh, Marian, et al.
Publicado: (2016)

Inflammation in atherosclerotic cardiovascular disease
por: Shah, Prediman K., et al.
Publicado: (2019)

The Effect of the PCSK9 Inhibitor Evolocumab on Aldosterone Secretion among High Cardiovascular Risk Patients: A Pilot Study
por: Izkhakov, Elena, et al.
Publicado: (2021)

Lipid lowering effects and safety of evolocumab in Chinese patients at very high cardiovascular risk: a single-center study
por: Chai, Meng, et al.
Publicado: (2023)

Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction
por: Henry, Courtney A, et al.
Publicado: (2016)

Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up
por: Dixon, Dave L, et al.
Publicado: (2017)

Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients
por: Huang, Chin-Chou, et al.
Publicado: (2019)

Sudden Fall in the Lipid-Lowering Effect of Evolocumab: The Butler Is Not Always Guilty
por: Fogacci, Federica, et al.
Publicado: (2021)

Sudden Fall in the Lipid-Lowering Effect of Evolocumab: The Butler Is Not Always Guilty
por: Fogacci, Federica, et al.
Publicado: (2021)

The effect of evolocumab alone and in combination with atorvastatin on atherosclerosis progression and TLRs expression
por: Saud, Ali, et al.
Publicado: (2023)

Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden
por: Landmesser, Ulf, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4dgdvjfvoa9kfkrvsikre0uvvn